Studies presented at the annual meting of the Society of Gynecologic Oncology, in Chicago, evaluated the efficacy of an experimental vaccine and an angiogenesis inhibitor in preventing the recurrence of ovarian cancer.
An experimental vaccine and a drug already on the market each may help slow down advanced ovarian cancer, 2 new studies suggest. In one, of just 31 patients, researchers found that adding the vaccine to standard treatment staved off a recurrence in women who had advanced-stage ovarian cancer.
The other study, involving women with recurrent ovarian cancer, found that administering the drug Avastin after surgery and chemotherapy stalled the cancer's progression, versus surgery and chemo alone.
The findings are to be presented Saturday at the annual meeting of the Society of Gynecologic Oncology (SGO), in Chicago. Studies reported at meetings are usually considered preliminary until they're published in a medical journal.
Link to the complete article in U.S. News & World Report: